The use of hemp oil (also known as hemp seed oil or, when containing cannabinoids, hemp-derived CBD oil) for Fibromyalgia Syndrome (FMS) is primarily justified by emerging scientific interest, though high-quality clinical evidence is limited. Hemp oil contains various compounds, including omega fatty acids, antioxidants, and—if it is a full-spectrum extract—cannabinoids like cannabidiol (CBD). CBD, in particular, has been of interest due to its potential effects on pain, inflammation, and central nervous system signaling.

Some small-scale clinical trials and numerous anecdotal reports suggest that CBD may help alleviate chronic pain and improve sleep, two major symptoms of FMS. For example, a 2019 cross-sectional study in the journal Journal of Clinical Rheumatology reported that CBD use was associated with self-reported symptom relief in fibromyalgia patients. However, these studies were limited by design (e.g., lack of placebo controls, small sample sizes).

The mechanism is believed to involve modulation of the endocannabinoid system, which plays a role in pain regulation, stress response, and immune function. Nevertheless, systematic reviews (including a 2021 review in Frontiers in Pharmacology) have concluded that while preclinical data and small studies are promising, there is insufficient robust clinical evidence to formally recommend hemp oil or CBD for FMS at this time.

In summary, the use of hemp oil for fibromyalgia is supported by preliminary scientific exploration, patient interest, and theoretical rationale, but strong clinical validation is currently lacking.